These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34529241)

  • 21. Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer.
    Ma M; Gan L; Jiang Y; Qin N; Li C; Zhang Y; Wang X
    Comput Math Methods Med; 2021; 2021():2140465. PubMed ID: 34422088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging.
    Kim JJ; Kim JY; Suh HB; Hwangbo L; Lee NK; Kim S; Lee JW; Choo KS; Nam KJ; Kang T; Park H
    Eur Radiol; 2022 Feb; 32(2):822-833. PubMed ID: 34345946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A preoperative radiogenomic model based on quantitative heterogeneity for predicting outcomes in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhou J; Bai Y; Zhang Y; Wang Z; Sun S; Lin L; Gu Y; You C
    Cancer Imaging; 2024 Jul; 24(1):98. PubMed ID: 39080809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL; Ding A
    Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
    Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
    Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
    Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
    PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
    Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
    Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
    Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic contrast-enhanced and diffusion-weighted MRI of invasive breast cancer for the prediction of sentinel lymph node status.
    Choi EJ; Youk JH; Choi H; Song JS
    J Magn Reson Imaging; 2020 Feb; 51(2):615-626. PubMed ID: 31313393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Abdelhafez AH; Musall BC; Adrada BE; Hess K; Son JB; Hwang KP; Candelaria RP; Santiago L; Whitman GJ; Le-Petross HT; Moseley TW; Arribas E; Lane DL; Scoggins ME; Leung JWT; Mahmoud HS; White JB; Ravenberg EE; Litton JK; Valero V; Wei P; Thompson AM; Moulder SL; Pagel MD; Ma J; Yang WT; Rauch GM
    Breast Cancer Res Treat; 2021 Jan; 185(1):1-12. PubMed ID: 32920733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence.
    Bae MS; Moon HG; Han W; Noh DY; Ryu HS; Park IA; Chang JM; Cho N; Moon WK
    Radiology; 2016 Feb; 278(2):356-64. PubMed ID: 26230976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
    Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
    Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of preoperative breast magnetic resonance imaging with a dedicated axillary sequence for the detection of axillary lymph node metastasis in patients with early ductal breast cancer.
    Ahn HS; Jang M; Kim SM; La Yun B; Lee SH
    Radiol Med; 2019 Dec; 124(12):1220-1228. PubMed ID: 31422573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
    Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
    Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DCE-MRI Performance in Triple Negative Breast Cancers: Comparison with Non-Triple Negative Breast Cancers.
    Chen H; Min Y; Xiang K; Chen J; Yin G
    Curr Med Imaging; 2022; 18(9):970-976. PubMed ID: 35232365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
    Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
    J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: A comparison with non-triple-negative breast carcinoma.
    Matsuda M; Tsuda T; Ebihara R; Toshimori W; Okada K; Takeda S; Okumura A; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
    Eur J Radiol; 2021 Sep; 142():109838. PubMed ID: 34217136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
    Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
    Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Usefulness of Combination of Diffusion-weighted Imaging and T2WI, Including Apparent Diffusion Coefficient in Breast Lesions: Assessment of Histologic Grade.
    Kim KW; Kuzmiak CM; Kim YJ; Seo JY; Jung HK; Lee MS
    Acad Radiol; 2018 May; 25(5):643-652. PubMed ID: 29339079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.